Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Anchorage-independent Growth
11%
Anoikis
11%
Applied Bioinformatics
11%
Autonomic Nervous System
33%
Biobank
11%
Biology Study
11%
Cancer Genome Atlas
11%
Cancer Onset
11%
CD31
11%
CD45
11%
Cell Biology
11%
Cholinergic Drugs
11%
Cholinergic Input
11%
Cholinomimetic
11%
CHRM3
11%
Chronic Liver Disease
11%
Clinical Research
11%
Cytotoxic Phenotype
11%
Densely Packed
11%
Disease Evolution
11%
FDA-approved Drugs
11%
Hepatocellular Carcinoma
100%
Hepatocyte Function
11%
Hepatocytes
100%
In Cancer
11%
Innervation
22%
Inter-patient
11%
Lenvatinib
11%
Liver
22%
Liver Carcinogenesis
11%
Liver Cells
11%
Liver Disease Progression
11%
Liver Support
11%
Liver Tumor
11%
Lymphocytes
11%
Mature Hepatocytes
11%
Muscarinic Receptors
100%
Netrin-1
11%
NeuN
11%
Neuronal Cells
100%
Neurotropic
11%
Novel Therapeutics
11%
Nurture
11%
Patient Stratification
11%
Pharmacological Inhibitors
11%
Pharmacology Studies
11%
Pharmacopoeia
11%
Phase II Trial
11%
Poor Prognosis
11%
Primary Hepatocytes
11%
Reconfiguration
11%
Redifferentiation
11%
Resistance to Treatment
11%
Response to Treatment
11%
Safety Level
11%
Single-cell RNA Sequencing Data
11%
Sorafenib
22%
Stochastic Optical Reconstruction Microscopy (STORM)
11%
Synaptophysin
11%
TEMRA
11%
Treatment Failure
11%
Tumor Stroma
11%
Tumoral
100%
Validation Cohort
11%
Vesicular Acetylcholine Transporter (VAChT)
11%
Whole-body
11%
Medicine and Dentistry
Anchorage Independent Growth
11%
Anoikis
11%
Autonomic Nervous System
33%
Chronic Liver Disease
11%
Clinical Research
11%
Cytotechnology
11%
Disease Course
11%
Disease Exacerbation
11%
Hepatocellular Carcinoma
100%
Hepatocyte
100%
Innervation
22%
Lenvatinib
11%
Liver Carcinogenesis
11%
Liver Cell
11%
Liver Function
11%
Liver Support
11%
Liver Tumor
11%
Lymphocyte
11%
Malignant Neoplasm
22%
Muscarinic Acetylcholine Receptor
100%
Neoplasm
11%
Nervous System Cell
100%
Netrin 1
11%
Neurotropic Agent
11%
Parasympatholytic
11%
Parasympathomimetic Drug
22%
Phase III Trials
11%
Receptor
11%
RNA Sequence
11%
Sorafenib
22%
Stroma
11%
Synaptophysin
11%
The Cancer Genome Atlas
11%
Vesicular Acetylcholine Transporter
11%
Pharmacology, Toxicology and Pharmaceutical Science
Cholinergic Receptor Blocking Agent
11%
Cholinergic Receptor Stimulating Agent
100%
Chronic Liver Disease
11%
Clinical Research
11%
Disease Course
11%
Disease Exacerbation
11%
Lenvatinib
11%
Liver Carcinogenesis
11%
Liver Cell Carcinoma
100%
Liver Tumor
11%
Malignant Neoplasm
33%
Muscarinic Receptor
100%
Neoplasm
11%
Netrin 1
11%
Neurotropic Agent
11%
Phase III Trials
11%
Receptor
11%
RNA-Sequencing
11%
Sorafenib
22%
Synaptophysin
11%
Vesicular Acetylcholine Transporter
11%